Clinical development of new formulations of cytotoxics in solid tumors

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 325-331

  Azim Jr , Hatem A ^a   Awada, Ahmad ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

amrubicin; chemotherapy; EndoTAG 1; new formulations; NKTR 102; pralatrexate

Indexed keywords

AMRUBICIN; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ENDOTAG 1; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEMETREXED; PRALATREXATE; PROBENECID; TOPOTECAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER PATIENT; CARDIOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; HYPOKALEMIA; INFECTION; LUNG CANCER; LUNG SMALL CELL CANCER; NEUTROPENIA; OVARY CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMATITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AMINOPTERIN; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMISTRY, PHARMACEUTICAL; FOLIC ACID ANTAGONISTS; HUMANS; NEOPLASMS; PACLITAXEL; TOPOISOMERASE I INHIBITORS;

EID: 84859873049     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328351fb29     Document Type: Review

References (47)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672. (Pubitemid 41464705)
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242. (Pubitemid 34438862)
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765.
5. Noguchi T, Ichii S, Morisada S, et al. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 1998; 89:1055-1060. (Pubitemid 28544782)
6. Azim HA Jr, Ganti AK. Treatment options for relapsed small-cell lung cancer. Anticancer Drugs 2007; 18:255-261. (Pubitemid 46192977)
7. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006; 24:5448-5453. (Pubitemid 46623179)
8. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008; 26:5401-5406.
9. Noguchi T, Ichii S, Morisada S, et al. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 1998; 89:1061-1066. (Pubitemid 28544783)
10. Phan VH, Moore MM, McLachlan AJ, et al. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol 2009; 5:243-257.
11. Saijo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nat Rev Clin Oncol 2009; 6:287-294.
12. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as secondline therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010; 28:2598-2603.
13. Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of singleagent amrubicin or topotecan as second-line treatment in patients with smallcell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011; 29:287-293.
14. Jotte R, Von Pawel J, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). J Clin Oncol 2011; 29 (Suppl):abstract 7000.
15. O'Brien ME, Konopa K, Lorigan P, et al. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer: EORTC 08062. Eur J Cancer 2011; 47:2322-2330.
16. Kaneda H, Okamoto I, Hayashi H, et al. Phase II trial of amrubicin for secondline treatment of advanced nonsmall cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401). J Thorac Oncol 2010; 5:105-109.
17. Yoshida H, Sekine I, Tsuta K, et al. Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol 2011; 41:897-901.
18. Arriola E, Rodriguez-Pinilla SM, Lambros MB, et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 2007; 106:181-189. (Pubitemid 350045015)
19. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011; 29:1578-1586.
20. Horio Y, Osada H, Shimizu J, et al. Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines. Cancer Chemother Pharmacol 2010; 66:237-243.
21. Perez-Soler R. Liposomes as carriers of antitumor agents: toward a clinical reality. Cancer Treat Rev 1989; 16:67-82. (Pubitemid 19225851)
22. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-1598. (Pubitemid 32778603)
23. Thurston G, McLean JW, Rizen M, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101:1401-1413. (Pubitemid 28166838)
24. Strieth S, Eichhorn ME, Sauer B, et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 2004; 110:117-124. (Pubitemid 38507211)
25. Strieth S, Nussbaum CF, Eichhorn ME, et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 2008; 122:452-460. (Pubitemid 350234735)
26. Strieth S, Eichhorn ME, Werner A, et al. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res 2008; 14:4603-4611.
27. Eichhorn ME, Ischenko I, Luedemann S, et al. Vascular targeting by Endo-TAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 2010; 126:1235-1245.
28. Awada A, Bondarenko IN, Tarasova O, et al. Results of the first randomized phase II study of cationic liposomal paclitaxel (ENDOTAG-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol 2010; 21:viii5, LBA12.
29. Lohr M, Bodoky G, Folsch UR, et al. Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: a phase II trial. J Clin Oncol 2009; 27 (Suppl):abstract 4526.
30. Eichhorn ME, Becker S, Strieth S, et al. Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging. Cancer Biol Ther 2006; 5:89-96. (Pubitemid 43234984)
31. Fasol U, Frost A, Buchert M, et al. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann Oncol 2011. [Epub ahead of print]
32. Kuhnel JM, Chiao JH, Sirotnak FM. Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in Fisher rat 3T3 cells. J Cell Physiol 2000; 184:364-372. (Pubitemid 30625500)
33. Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 1999; 19:91-122. (Pubitemid 29380598)
34. Serova M, Bieche I, Sablin MP, et al. Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. Br J Cancer 2011; 104:272-280.
35. Sirotnak FM, DeGraw JI, Schmid FA, et al. New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 1984; 12:26-30. (Pubitemid 14216734)
36. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29:1182-1189.
37. Krug LM, Ng KK, Kris MG, et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 2000; 6:3493-3498.
38. Krug LM, Azzoli CG, Kris MG, et al. 10-Propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated nonsmall cell lung cancer. Clin Cancer Res 2003; 9:2072-2078. (Pubitemid 36687627)
39. Patel JD, Azzoli CG, Weems GA, et al. Results of a randomized phase IIb study estimating overall survival of pralatrexate versus erlotinib in platinumpretreated NSCLC. J Clin Oncol 2011; 29 (Suppl)abstract 7554.
40. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14:253-263.
41. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human nonsmall-cell lung cancer cells. Mol Pharmacol 2005; 68:110-118. (Pubitemid 41002949)
42. Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in nonsmall cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011; 74:132-138.
43. Krug LM, Heelan RT, Kris MG, et al. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol 2007; 2:317-320. (Pubitemid 47181715)
44. Azzoli CG, Krug LM, Gomez J, et al. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clin Cancer Res 2007; 13:2692-2698. (Pubitemid 46788037)
45. von Hoff DD, Jameson GS, Borad MJ, et al. First phase 1 trial of NKTR-102 (Peg-Irinotecan) reveals early evidence of broad antitumor activity in three different schedules. EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics' Meeting; 2008. Poster no. 595.
46. Awada A, Chan S, Jerusalem G, et al. Significant antitumor activity in a randomized phase 2 study comparing two schedules of NKTR-102 in patients with pretreated metastatic breast cancer. J Clin Oncol 2011; 29 (Suppl)abstract 1034.
47. & Vergote IB, Micha JP, Pippitt CH Jr et al. Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer. J Clin Oncol 2010; 28 (Suppl)abstract 5013.